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Abstract
Background: Poor adherence to medication is one of the limitations in the treatment of cardiovascular diseases, thereby increasing
the risk of premature death, hospital admissions, and related costs. There is a need for simple and easy-to-implement interventions
that are based on patients’ perspectives, beliefs, and perceptions of their illness and medication.
Objective: The objective is to test the effectivity of this intervention to improve medication adherence in patients with established
cardiovascular disease, that is, in secondary prevention.
Methods: In this study the effect of a personalized visualization of cardiovascular risk levels through a website aiming at
supporting self management in combination with a group consultation and communication intervention by a nurse on adherence
to treatment in 600 patients with manifest cardiovascular diseases will be assessed. The health belief model was chosen as main
theoretical model for the intervention.
Results: Primary outcome is adherence to treatment calculated by refill data. Secondary outcomes include the Beliefs about
Medication Questionnaire and the Modified Morisky Scale. Patients are followed for one year. Results are expected by 2015.
Conclusions: This study assesses adherence to treatment in a high-risk cardiovascular population by applying an intervention
that addresses patients’ capacity and practical barriers as well as patients’ beliefs and perceptions of their illness and medication.
ClinicalTrial: ClinicalTrials.gov NCT01449695; https://clinicaltrials.gov/ct2/show/NCT01449695 (Archived by WebCite at
http://www.webcitation.org/6kCzkIKH3)
(JMIR Res Protoc 2016;5(3):e187)   doi:10.2196/resprot.5750
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Introduction
Background and Rationale
According to the World Health Organization, almost 50% of
all chronic patients do not adhere to their prescribed drug
regimen [1]. This is also true for cardiovascular diseases (CVD);
only 60% of all cardiovascular patients adhere to their
cardiovascular medications (eg, statins, antihypertensives,
antithrombotic agents) [2]. This prevalence is similar across all
individual CVD medications and occurred in patient who take
these medications for primary and secondary prevention of CVD
[2]. These figures are startling given that poor adherence results
in an increased risk of death in cardiovascular patients [3-5].
Current methods for improving adherence are mostly complex
and have limited effectiveness; simple interventions that are
easy to implement in daily practice are preferred [6]. Evidence
suggests that interventions should be based on the patients’
perspective [7], target patients’ capacity and practical barriers,
and address their beliefs and perceptions regarding illness and
medication [8,9]. In CVD, life-long adherence is important, and
interventions should improve patients’ intentions to take
medication as well as solve emergent practical barriers.
These principles were used in the development of the current
trial. Specifically, the intervention is based on the health belief
model (HBM) [10,11], tailored for the specific purpose of this
trial. HBM provides a useful framework for designing behavior
change strategies [12]. It is based on the understanding that a
person will take health‐related action (eg, being adherent to
cardiovascular medication) given four main factors. The first
two factors are perceived susceptibility and perceived severity:
understanding of the high personal risk and seriousness of a
condition (eg, because of the cardiovascular event in the past I
am at greater risk for another cardiovascular event). The third
factor is perceived benefit, or a belief that a negative health
condition can be avoided (eg, being adherent to the
cardiovascular medication can help to prevent another
cardiovascular event). The last factor is perceived barriers. Cue
to action and self‐efficacy and the belief in the ability to
successfully undertake the recommended health action (eg, I
know how to take my medication on a daily basis) [12,13].
Trial Design and Aim of the Study
The study will use a single‐center, prospective, randomized
controlled clinical trial design and examine the effectiveness of
a new intervention that incorporates HBM and behavior change
strategies to improve adherent behavior in cardiovascular
patients. The intervention consists of a patient-based screening
method, a specific nurse-based intervention (structural
informative consulting and motivational counseling), and
personalized visualization of cardiovascular risk levels via a
website. The objective is to test the effectiveness of this
intervention to improve medication adherence in patients with
established CVD (ie, in secondary prevention).
Methods
Study Setting
Participants will be drawn from a hospital‐wide screening
program. This screening program is situated at the
cardiovascular outpatient clinics in an academic medical center
in Nijmegen, the Netherlands. All new patients diagnosed in
the last 6 months with acute coronary syndrome, peripheral
arterial disease, an aneurysm of the aorta, or stroke/transient
ischemic attack (TIA) and referred to the departments of vascular
surgery, neurology, or cardiology are automatically included in
this program.
Eligibility Criteria
From this population, participants aged 18 years and older will
be selected based on the following inclusion criteria: presence
of CVD (acute coronary syndrome, peripheral arterial disease,
an aneurysm of the aorta, or stroke/TIA), diagnosed in the last
6 months by a medical specialist, willingness to remain in
follow‐up for a period of one year, and provision of signed
informed consent. Exclusion criteria are pregnancy (reported
by the patient), severe comorbidity (eg, a mental health diagnosis
considered by a physician to be a contraindication), problems
with the Dutch language (reported by the nurse), or logistic
problems such as lack of computer access.
Intervention
For the intervention, participants will be split in three groups.
Participants in group I (control group) receive only usual care.
Group II participants receive usual care plus access to a
personalized website. For the group III participants, in addition
to usual care and access to the personalized website, the
intervention program will also include a single group
consultation of 60 minutes led by a nurse and a pharmacist
followed by two individual consultations of 30 minutes with a
nurse.
We want to test if treatment II (only the Web portal) can give
the same results as treatment III (the Web portal and the single
group consultation followed by two individual consultations).
The need for low-cost effective interventions in our health care
system led to the motivation for this 3-arm protocol.
Usual Care (Groups I, II, and III)
All new CVD patients receive the hospital‐wide screening
program according to the Dutch guidelines [14] (based on the
European guidelines [15]). The screening assesses
cardiovascular risk factors in all patients with CVD. It screens
for lifestyle risk factors, blood lipid levels, blood pressure, waist
circumference, body mass index, blood glucose levels, and a
family history of CVDs. Lifestyle is evaluated through a
questionnaire which is a compilation of existing validated
questionnaires regarding demographic data, smoking, alcohol
use, physical activity, and eating habits. For each of these
lifestyle issues, the patient’s motivation to change is evaluated
[16]. Adherence is measured by the Modified Morisky Scale
(MMS) [17] and the Beliefs about Medication Questionnaire
(BMQ) [18]. Medication use will be monitored. If necessary
and if the patients agree they attend consultations with a nurse
JMIR Res Protoc 2016 | vol. 5 | iss. 3 | e187 | p.2http://www.researchprotocols.org/2016/3/e187/
(page number not for citation purposes)
Sieben et alJMIR RESEARCH PROTOCOLS
XSL•FO
RenderX
based on motivational interviewing to help them lose weight,
stop using alcohol, or stop smoking.
According to European guidelines [15], all patients with
established CVDs (this means all participants of this trial) should
have antiplatelet therapy (eg, aspirin or clopidrogel) and a lipid
lowering drug (eg, simvastatin or atorvastatin). The use of
antihypertensive drugs is dependent on the systolic blood
pressure. Except for the specific additions for the study, all
participating and nonparticipating patients receive the same
regular preventive cardiovascular care including monitoring of
medication use. All patients receive regular vascular care from
their medical specialist.
Website (Groups II and III)
The website contains an individualized Web portal called
Interactive File Vascular Care (Interactive Dossier Vaatzorg,
or iVAZ). This is developed to support patient-based
self-evaluation and management [19,20]. Patients can log on
and see their own cholesterol levels, blood pressure, and lifestyle
(smoking habit, exercise, and eating habits) in a risk monitor.
Patients can ask questions by email to their nurses, and they can
enter changes in their medication. iVAZ provides risk
communication, the feedback of clinical outcome will be
provided individually, and patients are invited to be active in
managing their illness and medication.
Group and Individual Consultations (Group III)
For group III, the intervention program will also include a single
group consultation of 60 minutes led by a nurse and a pharmacist
followed by two individual consultations of 30 minutes with a
nurse.
During the group consultations patients receive information
about their disease, cardiovascular medication (statins and
antihypertensive and antithrombotic agents), and the importance
of treatment adherence. Patients will receive an information
booklet with all information presented during the plenary
session. At the end of this consultation patients are asked to
keep a diary of their medication intake during a 2-week period
and to set a personal goal for the upcoming individual
consultation with a nurse. The group consultation is regarded
as an efficient way to increase knowledge and understanding
of the risks. It also provides a gathering with other patients
(peers).
During individual consultations, the intervention is further
tailored based on the goal previously set, patient’s concerns,
and necessities using the results of the screening questionnaire
(see Data Collection). The following topics will be discussed
during the individual consultation: patient's motivation and
confidence (barriers, concerns, and positive self-motivational
statements about their adherence behavior), options for
increasing adherence to treatment, and a global summary of the
counseling session.
Both the group and the individual consultations take place at
the outpatient clinic. The involved nurses have had training in
motivational interviewing [21] and were especially trained for
this intervention by a psychologist.
For each of the constructs, we used the recommended behavior
change strategies [12,13]. We tailored the intervention further
by using the taxonomy of Abraham and Michie [22,23] and the
coding manual by de Bruin [24] to categorize the behavior
change techniques to be included in the intervention. For each
of the components of HBM, the determinants, techniques, and
application strategy were developed and are detailed in Figure
1-4.
Figure 1. Techniques and applications influence perceived susceptibility in the current trial. The main determinant behind perceived susceptibility is
a lack of knowledge regarding prescribed medications and the influence on risk reduction.
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Figure 2. Techniques and applications influence perceived severity in the current trial. The main determinant behind perceived severity is patients’
beliefs, perception and management of their illness (awareness, outcome expectations).
Figure 3. Techniques and applications influence perceived benefits in the current trial. The main determinant behind perceived benefits is patients'
beliefs, perceptions, and management of their illness (awareness).
Figure 4. Techniques and applications influence perceived barriers, cue to action, and self-efficacy in the current trial. The main determinant behind
perceived barriers is skills and self-efficacy.
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Results
Primary Outcome
The primary outcome of our study is adherence to the CVD
medication (classified by the Anatomic Therapeutic Chemical
classification system) measured with a dedicated calculation of
refill data of the used plated aggregation inhibitors and lipid
modifying agents obtained from patient’s pharmacy.
Refill records of computerized pharmacy systems will be
collected from 3 years prior to a patient’s cardiovascular event
through up to 3 years after the study follow‐up period.
Prescription records include the names of all of the dispensed
drugs, prescribed daily dose, quantity dispensed at each
pharmacy fill, and the dates of the prescription fills. Adherence
will be calculated for the CVD medications as the theoretical
duration divided by the period between the start date and the
date of the last prescription filled. The theoretical duration will
be calculated by dividing the number of units dispensed by the
prescribed daily dose [25].
Patients with an adherence level of at least 80% will be classified
as adherent, and patients with an adherence level less than 80%
will be classified as nonadherent. Secondary prevention studies
showed that patients with an adherence of less than 80% have
an increased risk of death [26].
Refill adherence rates have been used extensively for the
assessment of drug acquisition and dispensing. Compared with
electronic monitoring, refill data provide researchers with a
relatively simple method for investigating exposure to
medication in large populations [27-29]. Moreover, this method
is suitable for investigating long‐term persistence to treatment
and gaps in medication supply [30].
Secondary Outcomes
All secondary outcome measurements will be obtained just
before inclusion (in the usual care screenings program) and one
year after inclusion. The secondary outcome measurements
include clinical responses to drug therapy (eg, cholesterol level),
self-report questionnaires, and changes in systolic blood
pressure.
Clinical responses to drug therapy will be recorded. A recorded
low-density lipoprotein cholesterol level above 20% of
preestimated low-density lipoprotein cholesterol reduction
during follow-up will be considered as possible indication of
poor adherence. If the patient also uses antihypertension drugs,
the blood pressure on baseline will be compared to blood
pressure after one year and will need to be within target blood
pressure for cardiovascular risk management (systolic <135 mm
Hg). These office blood pressure measurements are performed
according to the recommendations of the European Society of
Hypertension [15] with a validated automated device; data will
be based on a mean of four office measurements.
Second, two validated self-report questionnaires will be used.
The MMS will be used to measure adherence [17]. Each of the
8 items measures a specific medication‐taking behavior. MMS
scores can range from 0 to 8 and can be classified into three
levels of adherence: low adherence (score of less than 6),
medium adherence (score of 6 to less than 8) and high adherence
(score of 8) [31]. The BMQ will be used to provide information
about the beliefs, perceived necessity, and concerns patients
have regarding their illness and prescribed medication [18].
Respondents indicate their degree of agreement with each
individual statement about medicines on a 5‐point Likert scale.
It is then possible to differentiate between patients on the basis
of their beliefs about the necessity of their medication and their
concerns about taking it. Patients can be classified into four
different categories: accepting (high necessity and low
concerns), ambivalent (high necessity and high concerns),
skeptical (high concerns and low necessity), and indifferent
(low concerns and low necessity) [32,33].
Participant Timeline
Baseline scores will be collected for all groups. Follow-up scores
will vary depending on group and will be collected at 6 and 12
weeks (all groups) and 16 and 28 weeks (intervention groups
II and III) (see Figure 5 for flow chart).
Sample Size
This study is mainly powered on the primary outcome, the
detection of a significant difference between the three degrees
of care (usual, additional website, additional counseling) on
medication adherence as determined by refill records of
computerized pharmacy systems. Based on previous research
in our population and data from the literature [26], we estimate
that the adherence at the start of the study will be 65% in each
group with a standard deviation (SD) of 30%. We hypothesize
that the intervention given in group II and the intervention given
in group III will result in an increase of 10% in adherence to
treatment, resulting in mean adherence rates of 75% and 85%
in groups II and III, respectively. To detect these differences in
medication adherence the estimated group size with a power of
80% and an alpha of .05 (2‐sided) would be 200 in each group,
resulting in 600 participants in total.
Recruitment
All cardiovascular patients who receive the regular
cardiovascular preventive care will be asked to participate by
a nurse when they arrive at the outpatient clinic for their
screening consult. Patients will receive a letter explaining the
study, documenting their ability to withdraw at any time without
explanation, and confirming that their medical care will in no
way be influenced by their decision regarding participation. At
a minimum of 24 hours later, written consent will be sought by
a research assistant prior to the patient entering the study.
We chose to include all cardiovascular patients in our study
rather than only nonadhering patients as done in many other
studies [6,9,34]. The reason is that we plan to do a 3-year
follow-up and want to be able to see how adherence develops
over time for initial adherers and nonadherers alike.
Assignment of Interventions
Patients who meet the criteria and consent to participate will
then be randomized by the nurse stratified by department (eg,
neurology, vascular surgery, and cardiology) in a 1:1:1 ratio
into one of the three groups using computer randomization.
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Blinding
The principal investigator and the researcher will be blind to
randomization. However, due to the need for active participation,
the patient, nurse, and pharmacist delivering the individual
consultations will not be blind to assignment of individuals in
group III.
Data Collection and Management
The primary data collected will be provided by the initial
screening. Obtained data from the screening are blood lipid
levels, blood pressure, waist circumference, body mass index,
blood glucose levels, and medication use. Lifestyle is evaluated
through a questionnaire which is a compilation of existing
validated questionnaires regarding demographic data, smoking,
alcohol use, physical activity, and eating habits. For each of
these lifestyle issues, patient’s motivation to change is evaluated
[16]. Adherence is measured by the MMS [17] and beliefs about
medication by the BMQ [18].
Figure 5. Patient flow chart.
To monitor whether the website intervention is used, log‐in
information per patient, expressed as the number of log‐ins and
times and dates of log-in, will be recorded.
To measure the nurses’ performance skills required in the
individual consultations, the behavior change counseling index
will be used [35]. This validated checklist aims to measure the
nurses’ competence in behavior change counseling and
adaptation of motivational interviewing in healthcare settings.
The group consultations are videorecorded and evaluated in
order to validate the quality of the motivational interviewing
techniques applied.
Data will be entered by the nurses who perform the screening
and the intervention consults in iVAZ. iVAZ is a secured
website which can only be entered by the participants by using
their social security codes and by selected nurses using security
codes. In addition, all patient pharmacists will receive a letter
of information about the trial, consent of the ethical committee,
and the informed consents of the participants. They will be
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asked to send the data on refill records of their computerized
pharmacy systems through a secured email address. All the data
will be anonymized according to the privacy protocols from the
ethical committee and imported by the researcher into SPSS
(IBM Corp).
Statistical Methods
The data will be analyzed based on the intention‐to‐treat
principle and evaluated using SPSS, with descriptive statistics
(mean, median, SD, and interquartile range) being determined
for all variables. The data will be presented in quantitative
format (eg, biometrics, laboratory results, blood pressure,
lifestyle scores, adherence score on the basis of refill data, and
the MMS) and in descriptions of observed effects (eg, change
in BMQ, determinants for adherence, evaluation of the use of
iVAZ, and appreciation of nurse intervention).
To evaluate the difference between the groups, an analysis of
variance test will be performed on the outcome measures for
the three patient groups. The independent variable will be the
three intervention groups. The dependent variable is medication
adherence measured with the dedicated calculation of refill data.
Specifically, we will compare the difference between the first
and last time-point between groups for the primary and
secondary outcomes measures. For the intervention groups II
and III, we will also compare the outcomes of the clinical data
at 16 and 28 weeks. To correct for multiple comparison, a
Duncan’s multiple range test will be performed. Furthermore,
we will perform a receiver operating characteristic (ROC) curve
analysis to compare the outcome of the screening instruments
(MMS and BMQ) with the pharmacy refill dates. In the ROC
curve plot, specificity of the questionnaire is on the x-axis and
sensitivity of the question is on the y-axis.
Plausible relations between parameters of cardiovascular risk
factors, motivation to change, socioeconomic class, and
parameters of adherence (calculated refill score and BMQ and
MMS scores) will be tested in a univariate manner. Individual
parameters will be tested for normality using the
Kolomogorov-Smirnov test in order to select adequate univariate
tests. Multiple logistic regression analysis will be performed to
assess the relative importance of selected parameters for the
likelihood of low adherence, as defined by the refill data
algorithm. In all analyses, potential confounders will be included
if they independently changed the beta coefficient for dedicated
calculation of refill data by at least 5% or when consensus about
inclusion existed within the team of researchers supported by
clinical evidence from literature.
Missing data is unfortunately very common in eHealth research.
We follow the recommendation for eHealth research to use the
multiple imputation technique in SPSS when analyzing our
dataset with missing observations [36].
Ethics and Dissemination
The study protocol has been approved by the local ethical
committee before inclusion of patients into the study. The study
has been registered (trial registration ID number NCT01449695,
approved May 2011). Subjects may leave the study protocol at
any time for any reason without any consequences for regular
cardiovascular care. The investigator or patient specialists may
also decide to withdraw a subject from the study for urgent
medical reasons.
Discussion
Nonadherence to medication prescriptions in cardiovascular
patients reduces the positive effects of medical treatment in
chronic care. However, improvement of medication adherence
in these patients is a serious challenge. Patient beliefs,
perceptions, and management of medication, their illness
(intentional nonadherence), and skills to integrate medication
taking in their daily life (unintentional nonadherence) need to
be addressed to make an intervention successful.
There is no one‐size‐fits‐all solution for nonadherence [9,34]
nor does previous research provide evidence to choose a single
intervention [37]. By reviewing the literature it becomes evident
that determinants for nonadherent behavior are complex, and
underlying theory for a successful intervention is frequently
lacking [34,38,39]. In a review of 193 health behavior change
articles, only 36% of the authors mentioned a theory and only
22% of them applied the theory [40].
We based our method on HBM, adopted the approach of Horne
[41], and defined the main determinants of nonadherent behavior
in intentional and nonintentional determinants. Because we
address both types of determinants, we expected to develop an
intervention that will be more successful than most existing
interventions, which only take into account one of these sets of
determinants.
Specifically, by choosing a group consultation, information is
provided in an efficient manner and the patient is given an
opportunity to discuss the need for adherence (intentional
nonadherence) as well as getting practical information
(unintentional adherence) with peers. Further tailoring the
intervention in individual contacts provides the opportunity for
the nurse to identify the need to change objectives of
unintentional or intentional nonadherence (or a mix of both).
These individual consultations are patient‐centered, with
emphasis on patient perspectives and shared decision making
[42]. The individual website and visualization of personal
cardiovascular risk furthermore addresses one of the difficulties
in cardiovascular adherence: awareness of the influence of taking
medication on personal cardiovascular risk [40]. Lastly, the
combination of Web-based intervention with face-to-face contact
is expected to give better results than either alone [43]. Based
on this integration of factors, we hope that the resulting data of
this trial will contribute important knowledge about adherence
in this population.
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